Can Big 4 versus Non-Big 4 Differences in Audit-Quality Proxies Be Attributed to Client Characteristics?

被引:552
|
作者
Lawrence, Alastair [1 ]
Minutti-Meza, Miguel [1 ]
Zhang, Ping [1 ]
机构
[1] Univ Toronto, Toronto, ON M5S 1A1, Canada
来源
ACCOUNTING REVIEW | 2011年 / 86卷 / 01期
关键词
Big 4 versus non-Big 4 audit quality; discretionary accruals; ex ante cost-of-equity capital; analyst forecast accuracy; propensity-score matching; attribute-based matching; NONAUDIT SERVICES; PROPENSITY SCORE; CORPORATE GOVERNANCE; SELECTION BIAS; FEES; INCENTIVES; LITIGATION; ESTIMATOR; SAMPLE; TESTS;
D O I
10.2308/accr.00000009
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
This study examines whether differences in proxies for audit quality between Big 4 and non-Big 4 audit firms could be a reflection of their respective clients' characteristics. In our analyses, we use three audit-quality proxies-discretionary accruals, the ex ante cost-of-equity capital, and analyst forecast accuracy-and employ propensity-score and attribute-based matching models in attempt to control for differences in client characteristics between the two auditor groups while estimating the audit-quality effects. Using these matching models, we find that the effects of Big 4 auditors are insignificantly different from those of non-Big 4 auditors with respect to the three audit-quality proxies. Our results suggest that differences in these proxies between Big 4 and non-Big 4 auditors largely reflect client characteristics and, more specifically, client size. We caution the reader that this study has not resolved the question, although we hope that it encourages other researchers to explore alternative methodologies that separate client characteristics from audit-quality effects.
引用
收藏
页码:259 / 286
页数:28
相关论文
共 50 条
  • [41] Do Big 4 Auditors Enhance Audit Quality in China? A "Behind the Scenes Look"
    Chen, Songsheng
    Krishnan, Gopal, V
    Li, Wenying
    Zhang, Yinqi
    [J]. JOURNAL OF INTERNATIONAL ACCOUNTING RESEARCH, 2022, 21 (02) : 31 - 56
  • [42] The application of business risk audit methodology within non-Big-4 firms
    Kutum, Imad
    Fraser, Ian
    Hussainey, Khaled
    [J]. JOURNAL OF FINANCIAL REPORTING AND ACCOUNTING, 2015, 13 (02) : 226 - 246
  • [43] Big 4 fee premium and audit quality: latest evidence from UK listed companies
    Campa, Domenico
    [J]. MANAGERIAL AUDITING JOURNAL, 2013, 28 (08) : 680 - +
  • [44] Big-4 auditors and audit quality: a novel firm life-cycle approach
    Jain, Sonali
    Agarwalla, Sobhesh Kumar
    [J]. MEDITARI ACCOUNTANCY RESEARCH, 2023, 31 (05) : 1436 - 1452
  • [45] Effects of the Big 4 national and city-level industry expertise on audit quality in the United Kingdom
    Kharuddin, Khairul Ayuni Mohd
    Basioudis, Ilias G.
    Al Farooque, Omar
    [J]. JOURNAL OF INTERNATIONAL ACCOUNTING AUDITING AND TAXATION, 2021, 43
  • [46] Do Big 4 Auditors Provide Higher Audit Quality after Controlling for the Endogenous Choice of Auditor?
    Eshleman, John Daniel
    Guo, Peng
    [J]. AUDITING-A JOURNAL OF PRACTICE & THEORY, 2014, 33 (04): : 197 - 219
  • [47] "Big Boom" (4 Gy x 1) Radiation Treatment (RT) Versus "Big Boom" (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL)
    Hajj, Carla
    Lebow, Emily S.
    Lee, Jisun
    Fregonese, Beatrice
    Wijetunga, N. Ari
    Hubbeling, Harper
    Tringale, Kathryn R.
    Freret, Morgan E.
    Imber, Brandon S.
    Yahalom, Joachim
    [J]. BLOOD, 2022, 140 : 3622 - 3623
  • [48] Comment and Response to "Do Client Characteristics Really Drive the Big N Audit Quality Effect? New Evidence from Propensity Score Matching" by Mark DeFond, David H. Erkens, and Jieying Zhang
    DeFond, Mark
    Erkens, David H.
    Zhang, Jieying
    [J]. MANAGEMENT SCIENCE, 2017, 63 (11) : 3650 - 3653
  • [49] A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.
    Durm, Greg Andrew
    Furqan, Muhammad
    Feldman, Lawrence Eric
    Patel, Malini
    Hall, Richard Delmar
    Jalal, Shadia Ibrahim
    Birdas, Thomas J.
    Kesler, Kenneth
    Rieger, Karen Marie
    Ceppa, DuyKhanh
    Hanna, Nasser H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.
    Durm, Greg Andrew
    Furqan, Muhammad
    Hall, Richard Delmar
    Chiappori, Alberto
    Ma, Patrick C.
    Feldman, Lawrence Eric
    Kulkarni, Amit
    Haigentz, Missak
    Ganti, Apar Kishor
    Owen, Dwight Hall
    Sanborn, Rachel E.
    Hanna, Nasser H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)